Laron Z, Klinger B
Endocrinology and Diabetes Research Unit, Children's Medical Center of Israel, Petah Tikva.
Horm Res. 1993;40(1-3):16-22. doi: 10.1159/000183762.
Changes in body fat mass were studied in 25 untreated patients with Laron syndrome from childhood into adulthood. It was found that these patients, characterized by marked dwarfism, high plasma hGH and low serum insulin-like growth factor I (IGF-I), develop progressive and marked obesity and have a tendency for elevated serum cholesterol levels. Long-term treatment of 8 children and 5 adults with this syndrome with IGF-I (50-150 micrograms/kg/day s.c.) resulted in a significant decrease in subcutaneous fat in all patients and a lowering of the serum cholesterol and triglycerides, mainly in the adults. As in Laron syndrome the GH receptors are inactive, it is hypothesized that IGF-I exerts a direct effect on adipose tissue metabolism.
对25例未经治疗的拉伦综合征患者从儿童期到成年期的体脂量变化进行了研究。发现这些以显著侏儒症、高血浆hGH和低血清胰岛素样生长因子I（IGF-I）为特征的患者会出现进行性和显著的肥胖，并且有血清胆固醇水平升高的趋势。对8名患有该综合征的儿童和5名成人进行长期IGF-I治疗（皮下注射，50 - 150微克/千克/天）后，所有患者的皮下脂肪均显著减少，血清胆固醇和甘油三酯降低，主要是成人患者。由于在拉伦综合征中生长激素受体无活性，因此推测IGF-I对脂肪组织代谢有直接作用。
